{"prompt": "['Interferon beta-la', 'MESTRE-MS Study', 'EMR200136_597', '3.1', 'Responsibilities of the Investigator', 'The Investigator is responsible for the conduct of the study at his/her site. He/She will ensure', 'that the study is performed in accordance with the protocol and will ensure the quality and', 'integrity of data, following all applicable international and national guidelines.', 'This non-interventional study will not interfere with treatment prescription by Investigators.', 'Accordingly, the Investigator will decide in advance the best therapeutic strategy for each patient', 'according to current practice, regardless of the potential participation of this patient in the study.', 'Subsequently, if the prescribed treatment is in line with the study protocol, the Investigator will', 'consider the possibility of including the patient in the study.', 'The Investigator is responsible for adverse reaction (AR) recording and reporting, as specified in', 'Section 11.', 'CONFIDENTIAL', '10/60', 'INFORMATION', 'M']['Interferon beta-la', 'MESTRE-MS Study', 'EMR200136_597', '4', 'Abstract', 'Title', 'A Phase IV, prospective, multicenter, open label, uncontrolled,', 'non-interventional, single arm study to measure treatment satisfaction', 'of multiple sclerosis (MS) patients on Rebif after discontinuing', 'initial first-line treatment', 'Study', 'MESTRE-MS (MEasuring Satisfaction of Treatment with REbif after', 'acronym/Short title', 'initial treatment of MS)', '07 Oct 2016/Version 2.0', 'Study Protocol', 'Date / Version', 'Rationale and', 'The purpose of this study is to investigate treatment satisfaction in MS', 'background', 'patients, who have discontinued first-line MS oral or injectable MS', 'medication, and have initiated treatment with Rebif. MS patients who', 'are starting their first treatment for MS currently can be treated with', 'various oral or injectable medications. When solely considering the', 'route of administration of these medications it may appear that the oral', 'treatments are more patient friendly and convenient than the injectable', 'ones. In addition, certain weekly or daily first-line injection treatments', 'may be preferred over thrice weekly injections for unknown reasons. In', 'clinical trials, discontinuation rates due to adverse events (AEs) of', 'dimethyl fumarate (Tecfidera\u00ae) and of teriflunomide (AubagioR)', 'treated patients is 16% in both DEFINE and TENERE studies,', 'respectively. Furthermore, injectable treatment discontinuation varies', 'between 14% and 47%. It is important for patients to optimally utilize', 'first-line MS treatment options before escalating therapy to more', 'potentially dangerous second line therapies such as natalizumab,', 'fingolimod or alemtuzumab.', 'This Phase IV clinical study is being proposed to support decision', 'making for health care professionals (HCPs) and patients who have', 'decided to initiate MS treatment, and use arguments of patient', 'friendliness and convenience for their decision. Therefore, in this study', 'treatment satisfaction of Rebif is measured in MS patients who have', 'discontinued their initial MS treatment, and who have decided to start', 'Rebif as their follow-up treatment. Currently there is no information', 'describing the experiences with discontinuation of oral or injectable', 'medication and the initiation of the injectable therapy Rebif. This', 'information is crucial for HCPs and patients to be able to make a well', 'informed decision on what to expect of their treatment. In this study,', 'by measuring treatment satisfaction before and after Rebif treatment', 'we aim to evaluate the difference in treatment satisfaction (as', 'CONFIDENTIAL', '11/60', 'INFORMATION', 'M']['Interferon beta-la', 'MESTRE-MS Study', 'EMR200136_59', 'perceived by the patient), reasons to stop initial treatment, and', 'experience after alternative treatment initiation.', 'The clinical trial will contribute to the vast amount of data there is of', 'Rebif. This study will add the additional data on the perception of', 'treatment convenience and reasons for discontinuation of oral or', 'injectable first-line treatment.', 'Research question', 'Primary objective', 'and objectives', 'To determine the level of treatment satisfaction as measured with', 'the Treatment Satisfaction Questionnaire for Medication Version II', '(TSQM V II), in relapsing remitting MS (RRMS) patients who have', 'discontinued their initial oral or injectable MS treatment, and have', 'initiated treatment with Rebif.', 'Secondary objectives', 'To evaluate the change in annualized relapse rate (ARR) in patients', 'changing from initial oral or injectable forms of treatment to Rebif', 'To assess therapy adherence to Rebif', 'To determine the change in quality of life with Multiple Sclerosis', 'International Quality of Life Questionnaire (MusiQoL) between', 'Baseline, Month 6 and Month 12', 'To document the reasons for discontinuation of initial MS treatment', 'To evaluate the potential correlations between the following', 'measurements: TSQM V II, ARR, adherence, reasons for', 'discontinuation, MusiQoL and TSQM V II subscales', 'To assess the difference between TSQM V II subscales between', 'Baseline, Month 6 and Month 12.', 'Study Design', 'This is a prospective, multicenter, open label, uncontrolled,', 'non-interventional, single arm study to measure treatment satisfaction', 'of RRMS patients on Rebif after discontinuing initial first-line', 'treatment.', 'This study consists of three visits:', 'Visit 1: Baseline', 'Visit 2: Month 6', 'Visit 3: Month 12', 'This study will enroll RRMS patients who have discontinued their oral', 'or injectable first-line MS medication and have decided to initiate', 'CONFIDENTIAL', '12/60', 'INFORMATION', 'M']\n\n###\n\n", "completion": "END"}